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Abstract
Signiﬁcant advances have been made with respect to our understanding of the critical role of agents targeting
angiogenic pathways in the treatment of metastatic colorectal cancer (mCRC). The approval of 3 agents that target
angiogenic signaling, bevacizumab, ziv-aﬂibercept, and regorafenib, provides strong evidence that angiogenesis is an
important process in mCRC. The addition of bevacizumab to combination chemotherapy in the ﬁrst- and second-line
treatment of mCRC has resulted in meaningful improvement in overall and progression-free survival. The standard of
care for mCRC has evolved to incorporate cytotoxic chemotherapy as the backbone regimens (eg, FOLFOX [folinic
acid, 5-ﬂuorouracil, and oxaliplatin], FOLFIRI [folinic acid, 5-ﬂuorouracil, and irinotecan]) with or without bevacizumab,
and epidermal growth factor receptoretargeted therapies (eg, cetuximab, panitumumab) in the setting of wild-type
KRAS. The development of ziv-aﬂibercept in combination with FOLFIRI has improved clinical efﬁcacy in the second-
line treatment of mCRC. Regorafenib, a small-molecule multikinase inhibitor, has recently been approved by the US
Food and Drug Administration as single-agent therapy in the treatment of refractory and progressive mCRC. Each
of these agents has been integrated into an evidence-based—albeit, still evolving—treatment continuum for initial
treatment, treatment after ﬁrst progression, and treatment after second progression. However, the most effective
strategy for the use of these agents, and others in development remains unclear. This review provides an overview of
the current clinical evidence for the use of antiangiogenic agents targeting in the treatment of mCRC.
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Colorectal cancer (CRC) remains a major public health problem
in the United States with an annual incidence of nearly 150,000.1
Worldwide, it is estimated that more than 1 million new cases of
CRC will be diagnosed each year. Approximately 20% of newly
diagnosed CRC is metastatic at the time of initial presentation, and
more than 50% of patients with early-stage CRC at initial diagnosis
will eventually present with metastatic disease. Despite signiﬁcant
progress in the treatment of metastatic CRC (mCRC) over the past
2 decades, the prognosis of mCRC is still quite poor. Although
median overall survival (OS) has improved to the point where it is now
in the range of 24 to 28 months, 5-year OS remains less than 10%.*This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/3.0/).
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http://dx.doi.org/10.1016/j.clcc.2014.02.001Systemic chemotherapy has been the main treatment modality
for patients with mCRC. For nearly 40 years, the ﬂuoropyrimidine
5-ﬂuorouracil (5-FU) was the only agent approved by the US Food
and Drug Administration (FDA) for the treatment of mCRC.
However, since the mid-1990s, considerable advances have been
made with 3 new cytotoxic agents and 5 targeted agents approved by
the FDA. The cytotoxic agents include irinotecan, a topoisomerase I
inhibitor, oxaliplatin, a third-generation platinum analogue, and
capecitabine, an oral ﬂuoropyrimidine. Bevacizumab, an anti-vas-
cular endothelial growth factor (VEGF) antibody, was approved in
2004, along with cetuximab, a chimeric anti-epidermal growth factor
receptor (EGFR) antibody. In 2006, panitumumab, a fully human
anti-EGFR antibody, was approved for use in the disease-refractory
setting, and in the fall of 2012, the anti-VEGF recombinant fusion
protein, ziv-aﬂibercept, and regorafenib, a multikinase small mole-
cule inhibitor, were approved as second- and third-line treatment
options, respectively.2 The combinations of a ﬂuoropyrimidine (5-
FU or oral capecitabine) with either oxaliplatin (FOLFOX [folinic
acid, 5-FU, and oxaliplatin] or XELOX [capecitabine and oxalipla-
tin]) or irinotecan (FOLFIRI [folinic acid, 5-FU, and irinotecan] or
XELIRI [capecitabine and irinotecan]) have been widely accepted
as standard cytotoxic chemotherapeutic regimens for the ﬁrst- and
second-line treatment of patients with mCRC.3-7Clinical Colorectal Cancer September 2014 - 135
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136 -With several recent new developments in antiangiogenic the-
rapy for mCRC, including the introduction of ziv-aﬂibercept and
regorafenib, there is a clear need to determine how best to seq-
uence and integrate these agents along with bevacizumab, the ﬁrst-
generation anti-VEGF antibody. Herein, we review the current
clinical recommendations for the treatment of mCRC with a par-
ticular focus on patients with disease progression after ﬁrst-line
antiangiogenic therapy in combination with chemotherapy. We also
review the clinical evidence for the potential role of sequencing of
these antiangiogenic agents.
The Biology of Angiogenic
Pathways
Vascular Endothelial Growth Factors and VEGF
Receptors
The VEGF family of ligands and receptors is one of the best-
characterized pathways for its role in pathologic angiogenesis.
VEGF-A and the structurally related VEGF ligands, VEGF-B, -C,
-D, and placental growth factor (PlGF) mediate their respective
biological effects through at least 3 different cellular receptors,
VEGF receptor (VEGFR)-1, -2, and -3, each of which have tyrosine
kinase activity (Fig. 1).8-16 The interaction of VEGF-A, which has
6 alternatively spliced isoforms, with VEGFR-2 is believed to
account for the main angiogenic activities of VEGF-A in stimulating
tumor angiogenesis.8 The speciﬁc function of VEGFR-1 in angio-
genesis has not been fully deﬁned, and its speciﬁc ligands, VEGF-B
and PlGF, are known to play a role in the maintenance of tumor
blood vasculature without a signiﬁcant role in the formation of new
tumor blood vessels.17,18
Antiangiogenic Agents for the Treatment of mCRC
Bevacizumab is a humanized immunoglobulin (Ig)-G 1 mono-
clonal antibody directed against VEGF-A. It binds all isoforms of
VEGF-A and blocks the subsequent binding of VEGF-A to its
cognate receptors, thereby inhibiting its biologic activity.11,12Figure 1 Antiangiogenic Agents and Their Targets
Abbreviations: PlGF ¼ placental growth factor; VEGF ¼ vascular endothelial growth factor;
VEGFR ¼ vascular endothelial growth factor receptor.
Clinical Colorectal Cancer September 2014Ziv-aﬂibercept is a soluble decoy receptor molecule composed
of the critical ligand-binding domains of human VEGFR-1 and -2
fused with the Fc portion of IgG.16,19 As such, it acts as a multiple
angiogenic factor trap that inhibits the binding of VEGF-A to its
cognate receptors (VEGFR-1 and VEGFR-2) and in contrast to
bevacizumab, it also inhibits the binding of 2 additional factors—
VEGF-B and PlGF—to their cell-surface receptor, VEGFR-1
(Fig. 1).9 Ziv-aﬂibercept binds VEGF-A, VEGF-B, and PlGF at low
picomolar concentrations, such that multiple pathways, including
VEGFR-2emediated angiogenesis and VEGFR-1emediated tumor
growth, endothelial cell proliferation, and/or bone marrow myeloid
progenitor recruitment, might be inhibited by ziv-aﬂibercept.20,21
Regorafenib is a small-molecule multikinase inhibitor that targets
a wide range of tyrosine kinases involved in oncogenesis, tumor
angiogenesis, and maintenance of the tumor microenvironment.
These kinases include VEGFR-1, -2, and -3, ﬁbroblast growth
factor receptor, platelet-derived growth factor receptor, RET,
TIE-2, DDR2, RAF-1, BRAF, and BRAF V600E.13,15 Thus, re-
gorafenib hits a much broader range of key cellular targets that go
beyond the VEGF-signaling pathway.13,15
Preclinical Data on Antiangiogenic
Agents
The currently available antiangiogenic therapies for mCRC differ
in their underlying mechanisms of action. Bevacizumab targets only
VEGF-A, and ziv-aﬂibercept targets VEGF-A and other VEGF
ligands, VEGF-B and PlGF. Regorafenib acts through the more
broad-spectrum action of tyrosine kinase inhibition, thereby
inhibiting the activity of all VEGFRs and other receptors (Fig. 1).
However, to date, it is unclear as to whether these differences in
mechanisms of action ultimately account for different levels of
clinical efﬁcacy in selected groups of patients.
There is preclinical evidence suggesting that differences between
bevacizumab and ziv-aﬂibercept might be clinically relevant. The
more efﬁcient and potent binding of ziv-aﬂibercept to VEGF-A, by
up to 3 logs, when compared with bevacizumab, has been well
documented in cell-free systems, and this enhanced ligand bind-
ing has been associated with more potent biologic activity.16,22 In
fact, in directly comparative in vitro studies, the binding of ziv-
aﬂibercept to VEGF-A has been reported to be between approx-
imately 10-fold and more than 100-fold more efﬁcient than that of
bevacizumab.16,22 The differences in VEGF-A binding between
these 2 agents, using cell-free systems, have also been reﬂected in
the more potent biologic activity of ziv-aﬂibercept, at least in the
assay systems that were studied.16,22 The human umbilical vein
endothelial cell assay showed that ziv-aﬂibercept at subnanomolar
concentrations nearly completely inhibited cell migration in res-
ponse to exogenously administered VEGF-A, and treatment with
bevacizumab, at the same concentrations, resulted in only 50%
inhibition, with greater drug concentrations required for com-
plete inhibition.16,22 This study showed that approximately 5-fold
greater concentrations of bevacizumab when compared with ziv-
aﬂibercept were needed for an equivalent level of inhibition of
human endothelial cell migration induced by VEGF-A.16 A dif-
ferent assay system demonstrated 27-fold greater inhibition of
VEGFR-1/VEGFR-2 signaling (calcium mobilization) induced by
VEGF-A with ziv-aﬂibercept compared with bevacizumab.22 It is
James J. Lee, Edward Chualso important to note that, although ziv-aﬂibercept and bevacizu-
mab can inhibit biologic activity induced by VEGF-A binding to
VEGFR-1, ziv-aﬂibercept can also inhibit biologic activity induced
by PlGF binding to VEGFR-1, and bevacizumab cannot (Fig. 1).22
Thus, ziv-aﬂibercept has expanded the range of potential anti-
angiogenic targets to include PlGF, in addition to VEGF-A and -B.
Regorafenib is a potent inhibitor of several angiogenic-associated
receptor tyrosine kinases (VEGFR-1, VEGFR-2, VEGFR-3, TIE-2)
with half-maximal inhibitory concentration (IC50) values ranging
from 4.2 to 311 nM in biochemical assays.13 Preclinical in vitro
studies showed that regorafenib inhibited the proliferation of mul-
tiple human CRC cell lines, including those with KRAS or
BRAF mutations, with IC50 values in the range of 1 to 10 mM.
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Regorafenib showed in vivo antitumor activity in multiple xenograft
models including Colo-205 (a human CRC cell line harboring the
BRAF V600E mutation).13 Of note, regorafenib showed superiority
over DC101, an anti-VEGFRe2 monoclonal antibody, in a highly
aggressive murine CT26 metastatic colon cancer model with respect
to tumor growth suppression, reduction in tumor vascularization,
antiangiogenic activity, apoptosis rate, prevention of liver meta-
stases, and reduction in macrophage inﬁltration.24
Clinical Development of
Antiangiogenic Agents in mCRC
First-Line Setting
The feasibility of combining antiangiogenic agents, such as
bevacizumab, with established cytotoxic chemotherapy regimens in
mCRC was demonstrated in 2004 with the pivotal randomized
phase III study investigating the combination of bevacizumab and
IFL (folinic acid, 5-FU, and irinotecan) chemotherapy for the ﬁrst-
line treatment of mCRC.25 This was the ﬁrst randomized phase III
study to document the clinical beneﬁt of bevacizumab with respect
to signiﬁcantly improving progression-free survival (PFS), response
rate (RR), and OS associated with IFL chemotherapy. The
NO16966 randomized phase III study also showed the clinical
beneﬁts of combining bevacizumab with oxaliplatin-based chemo-
therapy (XELOX or FOLFOX) in the ﬁrst-line setting, with a
signiﬁcant improvement in PFS.26 Collectively, data from theseTable 1 Key Clinical Trials of Anti-VEGF Therapies in the First-line
Trial Regimen RR
Bevacizumab
AVF2107g25 IFL with and without
bevacizumab (n ¼ 813)
45 versus 3
NO1696631,32 FOLFOX4/XELOX with and without
bevacizumab (n ¼ 1400)
38 versus 3
TREE-233 mFOLFOX6/bFOL/CapeOx with
bevacizumab (n ¼ 223)
52 versus 3
BICC-C34,35 FOLFIRI/mIFL with bevacizumab
(n ¼ 117)
58 versus 5
Ziv-aﬂibercept
AFFIRM36 mFOLFOX6 with and without
ziv-aﬂibercept (n ¼ 236)
49 versus 4
Abbreviations: bFOL ¼ bolus FU plus low-dose folinic acid and oxaliplatin; CapeOx ¼ capecitabine and
acid, 5-ﬂourouracil, and oxaliplatin; FOLFOX4 ¼ folinic acid, 5-ﬂuorouracil, and oxaliplatin; HR ¼
cancer; mFOLFOX6 ¼ modiﬁed FOLFOX6; mIFL ¼ modiﬁed IFL; OS ¼ overall survival; PFS ¼
XELOX ¼ capecitabine and oxaliplatin.phase III trials26,27 and other clinical studies27-30 have established a
clear role for bevacizumab in the ﬁrst-line setting of mCRC treat-
ment (Table 1).25,31-36 Moreover, recent studies have shown that
the clinical beneﬁt of bevacizumab, in the front-line setting, extends
to wild type and mutant KRAS disease. Although bevacizumab has
also been used in the front-line setting as part of conversion therapy
for the treatment of liver-limited disease, the potential role of bev-
acizumab and other antiangiogenic agents in patients with liver-only
metastatic disease is beyond the scope of this article.
Elderly Patients With mCRC. A signiﬁcant portion of elderly
patients with mCRC are less tolerant to ﬁrst-line treatment of oxa-
liplatin- or irinotecan-containing combination chemotherapy plus
antiangiogenic agents.37,38 The AVEX trial is an open-label,
randomized phase III trial to investigate the role of bevacizumab in
combination with the oral ﬂuoropyrimidine capecitabine in the
ﬁrst-line treatment of elderly mCRC patients who were not deemed
to be suitable candidates for oxaliplatin-based or irinotecan-based
chemotherapy regimens.39 In this study, the elderly population was
deﬁned as 70 years and older (median age of 76 years; range, 70-87
years). Patients (n ¼ 280) were randomly assigned to capecitabine
(1000 mg/m2 twice per day on days 1-14) alone or with bev-
acizumab 7.5 mg/kg every 3 weeks. Of note, median PFS was
signiﬁcantly longer in the bevacizumab plus capecitabine arm when
compared with capecitabine alone (9.1 months vs. 5.1 months;
hazard ratio [HR], 0.53; P < .0001). Although treatment-related
adverse events of Grade 3 or worse occurred in 53 (40%) of patients
in the combination group and 30 (22%) in the capecitabine group,
the overall side effects seen with the combination were easily
managed. Based on this study, the combination of bevacizumab and
capecitabine is now viewed to be an effective and well-tolerated
regimen for elderly patients with mCRC deemed not to be good
candidates for more aggressive cytotoxic chemotherapy.
Role of Maintenance Bevacizumab. Several clinical studies
(OPTIMOX2, COIN, and GISCAD) have investigated the
potential role of a chemotherapy-free and/or low-intensity main-
tenance treatment after induction chemotherapy for mCRC.Treatment of mCRC
, % PFS, Months OS, Months
5 (P ¼ .004) 10.6 versus 6.2 (HR, 0.54;
P < .001)
20.3 versus 15.6 (HR ¼ 0.66;
P < .001)
8 (P ¼ .99) 9.4 versus 8.0 (HR, 0.83;
P ¼ .0023)
21.3 versus 19.9 (HR, 0.89;
P ¼ .077)
9 versus 46 e 26.1 versus 20.4 versus 24.6
3 11.2 versus 8.3 (P ¼ .28) 28.0 versus 19.2 (P ¼ .037)
6 8.5 versus 8.8 (HR, 1.0) e
oxaliplatin CT regimen; FOLFIRI ¼ folinic acid, 5-ﬂuorouracil, and irinotecan; FOLFOX ¼ folinic
hazard ratio; IFL ¼ folinic acid, 5-ﬂuorouracil, and irinotecan; mCRC ¼ metastatic colorectal
progression-free survival; RR ¼ response rate; VEGF ¼ vascular endothelial growth factor;
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of maintenance treatment with a bevacizumab-containing regimen
after induction chemotherapy in the ﬁrst-line treatment of patients
with mCRC.
The MACRO TTD study was a randomized phase III trial to
investigate the efﬁcacy of bevacizumab alone versus bevacizumab
with XELOX as maintenance treatment after induction chemo-
therapy in the ﬁrst-line treatment of patients with mCRC.40
Patients (n ¼ 480) were randomly assigned to receive 6 cycles of
XELOX with bevacizumab every 3 weeks followed by maintenance
treatment until disease progression. There was no statistically sig-
niﬁcant difference in the median PFS and OS between bevacizumab
alone versus bevacizumab with XELOX. These data suggest that
maintenance therapy with single-agent bevacizumab might be an
appropriate option after induction XELOX with bevacizumab in the
ﬁrst-line treatment of mCRC patients.
The CAIRO3 study was a phase III study to investigate the
efﬁcacy of maintenance treatment with capecitabine with bev-
acizumab versus observation in mCRC patients after induction
treatment with 6 cycles of CAPOX (capecitabine/oxaliplatin) with
bevacizumab (CAPOX-B). The ﬁnal results of the CAIRO3 study
were recently presented at the 2014 American Society of Clinical
Oncology Gastrointestinal Cancers Symposium.41,42 Patients with
mCRC (n ¼ 558) who experienced stable disease or better after 6
cycles of CAPOX-B in the ﬁrst-line induction treatment, were
randomized between observation (arm A) or maintenance treat-
ment with capecitabine with bevacizumab (arm B). At ﬁrst pro-
gression, CAPOX-B was reintroduced in 76% of patients in arm A
and 47% in arm B until second progression. PFS1 was deﬁned as
time from randomization to ﬁrst progression, and PFS2 was
deﬁned as time from randomization to second progression. The
median PFS1 was 4.1 in arm A versus 8.5 months in arm B (HR,
0.44; 95% conﬁdence interval [CI], 0.36-0.53; P < .00001) and
the median PFS2 was 10.5 versus 11.8 months (HR, 0.81; 95%
CI, 0.67-0.98; P ¼ .028). Surprisingly, less than half of the
patients in arm B received CAPOX-B after PFS1, and there was no
signiﬁcant difference in median OS from time of randomization
after 6 cycles of CAPOX-B (18.2 months vs. 21.7 months; HR,
0.87; 95% CI, 0.71-1.06; P ¼ .156). However, a signiﬁcant dif-
ference in median PFS1 was observed with an HR of 0.44. Taken
together, the data from the CAIRO3 study suggest that the use of
bevacizumab with capecitabine as maintenance therapy after front-
line CAPOX-B induction chemotherapy might be a reasonable
treatment option.
Treatment Paradigm for Patients With Wild-Type KRAS. The
FIRE-3 study, previously known as AIO KRK-0306, was a
randomized multicenter trial to compare the efﬁcacy of FOLFIRI
with cetuximab with FOLFIRI with bevacizumab in the ﬁrst-line
treatment of patients with wild-type KRAS mCRC.43 Although
recruitment initially was independent of KRAS status, an amend-
ment limiting enrollment to only patients with wild type KRAS
tumors was subsequently implemented. Among 735 patients of the
intent-to-treat population, wild type KRAS was identiﬁed in 592
(no mutation in the exon 2 of KRAS). Of these, 297 patients were
randomized to the FOLFIRI with cetuximab arm and 295 to theClinical Colorectal Cancer September 2014FOLFIRI with bevacizumab arm. Although no differences in overall
response rate (62% vs. 58%; P ¼ .183) and PFS (10.0 months vs.
10.3 months; P ¼ .547) were observed between the 2 arms, OS was
signiﬁcantly improved in the FOLFIRI with cetuximab arm than in
the FOLFIRI with bevacizumab arm (28.7 months vs. 25.0
months; HR, 0.77; P ¼ .017).43
In a preplanned analysis of the effect of mutations in the EGFR
pathway on efﬁcacy, KRAS (exons 3, 4), NRAS (exons 2, 3, 4) and
BRAF (V600E) were sequenced in 407 patients, and the wild type
RAS patient group was further deﬁned as those without any
mutation in KRAS (exons 2, 3, 4) and NRAS (exons 2, 3, 4).44 The
RR within the wild type RAS patient group was not signiﬁcantly
different in the FOLFIRI with cetuximab arm versus the FOLFIRI
with bevacizumab arm. However, the OS in this newly deﬁned
wild type RAS patient group (n ¼ 342) was signiﬁcantly greater
with FOLFIRI with cetuximab (n ¼ 171) than with FOLFIRI
with bevacizumab (n ¼ 171) (33.1 months vs. 25.6 months; HR,
0.70; 95% CI, 0.53-0.92; P ¼ .01).44 In the wild type RAS patient
group, the OS was markedly superior with a difference of 7.5
months with FOLFIRI with cetuximab combination versus FOL-
FIRI with bevacizumab combination.
Taken together, this study suggests that wild type RAS status
should be analyzed before treatment with cetuximab-containing
chemotherapy. In addition, patients with wild type RAS might be
more likely to beneﬁt from a cetuximab-containing regimen in
the ﬁrst-line setting than a bevacizumab-containing regimen because
of the improvement in OS. However, the true clinical beneﬁt
of cetuximab in the front-line setting remains somewhat unclear
because the overall RRs and PFSs were nearly identical in the
cetuximab and bevacizumab arms. Another confounding issue is
that the cytotoxic chemotherapy backbone used in this study was
FOLFIRI. Because FOLFOX is the preferred cytotoxic regimen
used in the United States, it is not clear that the results of the FIRE-
3 trial can be directly extended to FOLFOX-based chemotherapy.
On that point, the results of the CALGB 80405 phase III study are
eagerly awaited, because this study addresses the very same issue as
FIRE-3 but physician selection allows patients to receive either
FOLFOX or FOLFIRI as the chemotherapy backbone with patients
randomized to receive either bevacizumab or cetuximab. The results
of this study are to be presented at this year’s 2014 American
Society of Clinical Oncology meeting.
Second-Line Setting
There are 3 key clinical trials that provide support for the
current use of antiangiogenic agents in the second-line setting
(Table 2).45-47 E3200 was a randomized study conducted by the
Eastern Cooperative Oncology Group that investigated bevacizu-
mab in combination with FOLFOX4 (folinic acid, 5-FU, and
oxaliplatin) for patients who had failed initial irinotecan-based
chemotherapy.45 More recently, the ML18147 trial investigated
the use of bevacizumab in the second-line setting in patients who
had progressed during use of a previous bevacizumab-containing
regimen (unlike E3200).46 Finally, the VELOUR trial was the ﬁrst
major registration trial to examine ziv-aﬂibercept in combination
with FOLFIRI for patients in whom a previous oxaliplatin-
containing regimen had failed.47
Table 2 Key Findings in the E3200, TML18147, and VELOUR Trials in mCRC
Trial End Point Control Arm Experimental Arm
Results
HR (95% CI) P
E320045 FOLFOX4 (n ¼ 291) FOLFOX4 with bevacizumab
(n ¼ 286)
OS OS 10.8 Months 12.9 Months 0.75 .0011
PFS 4.7 Months 7.3 Months 0.61 <.0001
RR 8.6% 22.7% e <.0001
ML1814746 Chemotherapy alone
(n ¼ 411)
Chemotherapy with
bevacizumab (n ¼ 409)
OS 9.8 Months 11.2 Months 0.81 (0.69-0.94) .0062
PFS 4.1 Months 5.7 Months 0.68 (0.59-0.78) <.0001
RRa 4% 5% e .31b
VELOUR47 FOLFIRI and placebo
(n ¼ 614)
FOLFIRI and ziv-aﬂibercept
(n ¼ 612)
OS 12.1 Months 13.5 Months 0.817 (0.713-0.937) .0032
PFS 4.67 Months 6.9 Months 0.758 (0.661-0.869) .0001
RR 11.1% 19.8% 8.5%-13.8% .0001
Abbreviations: FOLFIRI ¼ folinic acid, 5-ﬂuorouracil, and irinotecan; FOLFOX4 ¼ folinic acid, 5-ﬂuorouracil, and oxaliplatin; HR ¼ hazard ratio; mCRC ¼ metastatic colorectal cancer; OS ¼ overall
survival; PFS ¼ progression-free survival; RR ¼ response rate.
aConﬁrmed RR among patients with 1 or more measurable lesions at baseline.
bUnstratiﬁed c2 test.
James J. Lee, Edward ChuE3200. E3200 was a pivotal randomized phase III clinical trial
that formed the basis for the approval of bevacizumab by the FDA
in the second-line setting. Patients who had previously received a
ﬂuoropyrimidine/irinotecan-based regimen but no previous bev-
acizumab were randomly assigned to receive either bevacizumab
with FOLFOX4 or FOLFOX4 alone; a third arm that consisted of
bevacizumab therapy alone was subsequently discontinued because
of inferior clinical efﬁcacy relative to the other 2 chemotherapy-
containing arms.45 As shown in Table 2, at the median follow-up of
28 months, patients in the combination therapy group experienced
signiﬁcantly improved beneﬁts in OS (12.9 vs. 10.8 months; P ¼
.0011), PFS (7.3 vs. 4.7 months; P < .0001), and RR (22.7% vs.
8.6%; P < .0001).45 With respect to safety proﬁle, Grade 3 or 4
neuropathy, hypertension, bleeding, and vomiting occurred more
frequently in patients receiving the combination of FOLFOX with
bevacizumab compared with FOLFOX alone.45 Based on the results
of E3200, bevacizumab is presently recommended in the National
Comprehensive Cancer Network guidelines as second-line treat-
ment for patients who have not previously received bevacizumab in
the front-line setting.45 One limitation of this trial, however, was
that it was not speciﬁcally designed to address whether bevacizumab
could be continued beyond ﬁrst progression for patients who had
received bevacizumab in the ﬁrst-line setting. In addition, this study
did not speciﬁcally address whether bevacizumab was effective after
what is now known to be more effective chemotherapy combina-
tions using infusional 5-FU or capecitabine as the ﬂuoropyrimidine
backbone than bolus 5-FU.
ML18147. The ML18147 was a prospective, open-label, inter-
group, randomized, phase III study to assess the continuation of
bevacizumab beyond ﬁrst progression in patients who had pre-
viously received ﬁrst-line combination chemotherapy with bev-
acizumab.46 This study was originally initiated in 2006 at severalcenters in Germany (AIO KRK 0504). In 2008, centers in other
European countries were included to increase the statistical power of
the trial.46 A total of 820 patients were randomly assigned to receive
a chemotherapy regimen in the absence (n ¼ 411) or presence
(n ¼ 409) of bevacizumab. The primary end point of the study was
OS, which was deﬁned as time from randomization to death from
any cause; secondary end points included PFS, overall response, and
safety.46 All patients had received previous bevacizumab therapy
combined with the investigator’s choice of a ﬁrst-line chemotherapy
regimen, which included a ﬂuoropyrimidine with either irinotecan
or oxaliplatin, and because of this, the doses and schedules of in-
dividual agents, and the speciﬁc combination regimens, were dif-
ferent. Of note, the diagnosis of progressive disease for > 3 months
after the last bevacizumab dose, a ﬁrst-line PFS of < 3 months, and
the administration of < 3 months of continuous ﬁrst-line bev-
acizumab were all grounds for exclusion.46 The speciﬁc types of
chemotherapy regimens used were well balanced between treatment
arms, as were baseline clinical and demographic characteristics.46
For patients in the bevacizumab with chemotherapy group,
median OS was 11.2 months and median OS for the chemotherapy-
alone group was 9.8 months (HR, 0.81; 95% CI, 0.69-0.94;
P ¼ .0062). PFS also favored the bevacizumab-containing arm rel-
ative to chemotherapy alone (5.7 vs. 4.1 months; HR ¼ 0.68; 95%
CI, 0.59-0.78; P < .0001). There was no signiﬁcant difference in
conﬁrmed RR between the arms (Table 2; P ¼ .31). In a post hoc
analysis, the proportion of patients with disease control favored the
bevacizumab arm (275 [68%] vs. 220 [54%]; P < .0001).46 The
results for prespeciﬁed subgroup analyses were generally consistent
with those seen in the overall population; the beneﬁt of bevacizumab
in terms of PFS was also observed irrespective of KRAS mutation
status (for wild type KRAS: HR ¼ 0.61, P < .0001; for mutant
KRAS: HR¼ 0.70, P¼ .003) in an exploratory subgroup analysis.46
Interestingly, when the secondary end point of OS from the start ofClinical Colorectal Cancer September 2014 - 139
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acizumab therapy did not reach statistical signiﬁcance (23.9 months
vs. 22.5 months; P ¼ .17).
In terms of safety proﬁle, Grade 3 to 5 adverse events (overall:
64% and 57%, respectively) occurring in  2% of patients included
neutropenia (65 [16%] vs. 52 [13%]), diarrhea (40 [10%] vs. 34
[8%]), and asthenia (23 [6%] vs. 17 [4%]). Bevacizumab-related
safety events, including bleeding or hemorrhage (8 [2%] vs. 1
[<1%]), gastrointestinal perforation (7 [2%] vs. 3 [<1%]), and
venous thromboembolic events (19 [5%] vs. 12 [3%]) were
observed more commonly in the bevacizumab arm.46
The ﬁndings from the ML18147 study were the ﬁrst to dem-
onstrate that continuation of bevacizumab after disease progression
with an accompanying change in the cytotoxic chemotherapy
backbone conferred clinical beneﬁt in terms of OS and PFS for
patients who had received a previous bevacizumab-containing reg-
imen. It has been proposed that the development of resistance to
chemotherapy, which is often agent-speciﬁc, is unlikely to be
accompanied by resistance to antiangiogenic therapy. For this rea-
son, a biologic agent such as bevacizumab might continue to have
beneﬁt even after resistance to the initial chemotherapy component
of the regimen has emerged.46 Another possibility that cannot be
excluded, however, is that resistance to bevacizumab might also
develop, albeit at a slower rate than that observed with chemo-
therapy resistance. There are several potential mechanisms to
explain resistance to bevacizumab, and they include increased tumor
production of VEGF-A, increased production of alternative, more
biologically active forms of VEGF-A to facilitate a greater likelihood
for interaction with its cognate VEGF receptor, and increased
expression of other VEGF ligands, such as VEGF-B, VEGF-C,
VEGF-D, and PlGF.48,49 In fact, Kopetz and colleagues from the
M.D. Anderson Cancer Center have previously shown upregulation
of the VEGF ligand PlGF along with increased expression of certain
cytokines/chemokines, including basic ﬁbroblast growth factor,
hepatocyte growth factor, platelet-derived growth factor, matrix
metallopeptidase-9, stromal-derived factor-1, and macrophage che-
moattractant protein-3, when resistance to bevacizumab-containing
regimens developed in patients with mCRC.50
VELOUR. The recent approval of ziv-aﬂibercept by the FDA was
based on the results from the VELOUR trial, a multinational,
prospective, phase III, parallel-arm study. The objective of
VELOUR was to investigate the safety and efﬁcacy of ziv-aﬂiberceptTable 3 Results From VELOUR for Patients With and Without Previo
End Point Patient Subgroup
FOLFIR
Plac
OS, Months Overall population (n ¼ 1226) 12
OS Without previous bevacizumab
(n ¼ 853)
12
With previous bevacizumab
(n ¼ 373)
11
PFS, Months Without previous bevacizumab 5
With previous bevacizumab 3
Abbreviations: FOLFIRI ¼ folinic acid, 5-ﬂuorouracil, and irinotecan; HR ¼ hazard ratio; OS ¼ over
aHR for difference between FOLFIRI/placebo and FOLFIRI/ziv-aﬂibercept.
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line treatment of mCRC patients (n ¼ 1226) whose disease had
progressed during treatment with an oxaliplatin-containing regi-
men.47 The primary end point of this study was OS, with the
secondary end points being PFS and RR. Patients in the trial,
which included those with previous bevacizumab treatment, but
not previous irinotecan treatment, were required to have docu-
mented evidence of disease progression during or after the
completion of an oxaliplatin-containing regimen. However, selec-
tion was not based on the timing of their disease progression.47
Eligible patients were randomized (1:1) to FOLFIRI combined
with either ziv-aﬂibercept or placebo, and were stratiﬁed according
to previous bevacizumab treatment.47 Patient and disease charac-
teristics were similar between treatment arms, and the use of pre-
vious bevacizumab was reported for nearly 30% of patients.
There was a signiﬁcant improvement of median OS in the ziv-
aﬂibercept arm over the placebo arm (13.5 vs. 12.1 months; P ¼
.0032).47 The 2-year survival rate was 28% for patients who
received ziv-aﬂibercept versus 18.7% for placebo.47 The beneﬁt of
ziv-aﬂibercept on OS was consistent across the prespeciﬁed sub-
groups of previous bevacizumab use. In particular, approximately
30% of the VELOUR population had previously been treated with
bevacizumab. The results of this patient subset analysis, stratiﬁed
according to previous bevacizumab use, are summarized in Table 3.51
Ziv-aﬂibercept produced a consistent trend toward prolonged OS
(Table 3). A beneﬁt of ziv-aﬂibercept over placebo was also observed
for PFS and RR in the overall VELOUR population (Table 2), with
a trend for improved PFS also observed regardless of previous
bevacizumab use (Table 3).47,51
Further subset analyses of the VELOUR population were per-
formed to deﬁne a subgroup of patients who might derive increased
beneﬁt from use of the ziv-aﬂibercept and FOLFIRI combination.
Cancer recurrence during or within 6 months of completing adju-
vant oxaliplatin-based therapy is generally regarded as a poor
prognosis, and post hoc subset analysis of survival in the previous
bevacizumab use group was done after exclusion of patients with
early relapse.52 In the previous bevacizumab use group, 9 patients in
the ziv-aﬂibercept arm (n ¼ 186) and 8 in the placebo arm (n ¼
187) had recurrence during or within 6 months of completing
adjuvant oxaliplatin-based therapy and were excluded from this
analysis, and the remaining 177 patients in the ziv-aﬂibercept arm
and 179 patients in the placebo arm were included in this post
hoc analysis of survival. There was an improved median OS ofus Bevacizumab Treatment
I With
ebo
FOLFIRI With
Ziv-Aﬂibercept HR (95% CI)a
.1 13.5 0.817 (0.713-0.937)
.4 13.9 0.788 (0.669-0.927)
.7 12.5 0.862 (0.673-1.104)
.4 6.9 0.797 (0.679-0.936)
.9 6.7 0.661 (0.512-0.852)
all survival; PFS ¼ progression-free survival.
James J. Lee, Edward Chu2.14 months in the ziv-aﬂibercept arm versus the placebo arm
(13.80 vs. 11.66 months; HR, 0.812; 95% CI, 0.634-1.042). A
multivariate analysis identiﬁed a subset of patients with better
outcomes in the ziv-aﬂibercept arm: “better responders”; those with
good performance status (PS; 0 or 1),  1 metastatic site, and
without an early relapse after adjuvant chemotherapy.53 The “better
responders” subset included 404 of 612 patients in the ziv-aﬂi-
bercept arm and 406 of 614 patients in the placebo arm. In the
“better responders” subset, median OS was signiﬁcantly improved
by 3.1 months in the ziv-aﬂibercept arm (16.2 vs. 13.1 months;
adjusted HR, 0.73; 95% CI, 0.61-0.86). These results suggest that a
subgroup of patients with good PS, limited number of metastatic
sites, and without early relapse after adjuvant chemotherapy
might derive increased clinical beneﬁt from the ziv-aﬂibercept and
FOLFIRI combination.
The most commonly reported ( 5%) Grade 3 to 4 adverse
events included side effects that have been commonly associated
with VEGF inhibition (eg, hypertension, proteinuria) and other
events that are associated with irinotecan-based chemotherapy
(eg, neutropenia, diarrhea).54 Adverse events that led to study drug
discontinuation occurred in 26.8% of ziv-aﬂiberceptetreated
patients versus 12.1% of placebo-treated patients.47 A recent anal-
ysis from VELOUR examined the time course of adverse events.55
These investigators found that most Grade 3 or 4 adverse events,
including those related to chemotherapy (eg, diarrhea, infection,
stomatitis, neutropenia) and those commonly associated with VEGF
inhibition (eg, proteinuria, hypertension, hemorrhage), occurred
during the early treatment cycles, decreased during subsequent
cycles, and were generally manageable according to current clinical
practice risk management guidance. Moreover, they observed that
proteinuria was the most frequent cause of premature treatment
discontinuation, with 29 (4.7%) ziv-aﬂiberceptetreated patients
(n ¼ 611) discontinuing after an average of 7 cycles.55
Consistent with the primary analysis, additional supplemen-
tary analyses from VELOUR have documented a beneﬁt of ziv-
aﬂibercept in the population of patients remaining “on treatment”
(excluding events occurring > 28 days after the last treatment dose),
and in the North American population.56,57 Further analysis has
shown a continuous beneﬁt of ziv-aﬂibercept over time, such that
the longer the duration of treatment, the greater the magnitude of
clinical beneﬁt.58
Taken together, the results from VELOUR demonstrate a beneﬁt
of antiangiogenic therapy with ziv-aﬂibercept in combination with
FOLFIRI compared with FOLFIRI alone for patients who progress
during a ﬁrst-line regimen containing oxaliplatin. Clinical beneﬁt
was also observed in the subgroup of patients who had received
previous bevacizumab as part of their ﬁrst-line treatment regimen.
Accordingly, ziv-aﬂibercept is now considered an appropriate
treatment option for patients in the second-line setting.
Comparison of the ML18147 and VELOUR Clinical Studies.
Because the ML18147 and VELOUR studies provide evidence for
the clinical beneﬁt of an antiangiogenic therapy in patients with
previous bevacizumab treatment, the potential differences between
these 2 studies should be considered.46,47 It should be noted that
the main objectives of these trials were entirely different. VELOURwas conducted to determine the safety and efﬁcacy of ziv-aﬂibercept
in patients who had received previous oxaliplatin therapy, and most
patients in VELOUR (approximately 70%) were bevacizumab-
naive. In contrast, ML18147 was conducted in patients who had
received previous bevacizumab therapy in an effort to determine the
beneﬁt and tolerability of continued bevacizumab therapy.46,47 In
addition, patients in ML18147 whose disease had progressed within
the ﬁrst 3 months after initial ﬁrst-line therapy with bevacizumab
were excluded, as were patients whose disease had progressed > 3
months after the previous ﬁrst-line dose of bevacizumab and those
whose disease progressed rapidly during a bevacizumab-containing
initial regimen. As a result, among the large and diverse patient
population studied in VELOUR, only a small subgroup would have
been eligible for participation in ML18147. Another distinguish-
ing feature is that VELOUR was double-blinded and placebo-
controlled, and ML18147 was an open-label study, and patients
who received < 3 consecutive months of ﬁrst-line bevacizumab
treatment were ineligible. Moreover, patients in the VELOUR trial
received the same chemotherapy regimen (FOLFIRI) in both arms,
whereas the speciﬁc chemotherapy regimen used in the ML18147
study was based on investigator’s choice. It remains unclear as to
whether the more restricted design of ML18147 might have selected
for more favorable prognosis and/or bevacizumab-responsive patients
in their particular study population.
Beyond the Second-Line Setting
The CORRECT trial was a global, randomized, multicenter,
placebo-controlled study that was conducted in various countries in
North America, Europe, Asia, and Australia. This study was
designed to assess the efﬁcacy and safety of regorafenib for patients
with mCRC whose disease had progressed during or within the last
3 months of therapy, despite all approved therapies.14 As a multi-
national study, standard therapies varied but had to include a ﬂu-
oropyrimidine, oxaliplatin, irinotecan, bevacizumab, and cetuximab
or panitumumab (for wild type KRAS tumors).14 Participants were
randomized approximately 2:1 to receive regorafenib (n ¼ 505) or
placebo (n ¼ 255) plus best supportive care. This trial showed a
median OS of 6.4 months versus 5.0 months for regorafenib and
placebo, respectively (HR ¼ 0.77; 95% CI, 0.64-0.94; 1-sided P ¼
.0052).14 A similar beneﬁt in PFS was also seen for patients who
received regorafenib relative to those who received placebo (HR ¼
0.49; 95% CI, 0.42-0.58; P < .0001), with a median PFS of 1.9
months and 1.7 months, respectively. Despite improvements in OS
and PFS with regorafenib treatment, patients’ health status and
quality of life appeared to decline at a similar rate in both arms.14
The most common Grade 3 and 4 adverse events with regorafenib,
included VEGF-related hypertension, and hand-foot skin reaction,
fatigue, diarrhea, and rash/desquamation, with 333 (67%) and 57
(23%) of patients in the regorafenib and placebo groups, respectively,
experiencing an adverse event that required dose reduction or
modiﬁcation.14
Current Treatment Options for
mCRC
Combination regimens including a ﬂuoropyrimidine (5-FU or
capecitabine) with either oxaliplatin (FOLFOX or XELOX) orClinical Colorectal Cancer September 2014 - 141
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142 -irinotecan (FOLFIRI) have been widely accepted as standard ﬁrst-
line treatment for patients with mCRC.3-7 The addition of bev-
acizumab to any of these combination regimens is reasonable for
patients who are appropriate candidates for aggressive therapy. The
addition of an anti-EGFR antibody (eg, cetuximab or pan-
itumumab) might also be indicated in selected patients with wild
type KRAS status.
The current options for patients whose disease has progressed
after the initial therapy with or without bevacizumab include a
change in the cytotoxic chemotherapy regimen (dependent on the
initial therapy), with or without the addition of an anti-VEGF
molecule, which could include bevacizumab or ziv-aﬂibercept.
For wild type KRAS patients, the inclusion of an anti-EGFR agent
(eg, cetuximab or panitumumab) in the overall treatment algorithm
should also be considered.
Patients whose disease progresses after all previously approved
ﬁrst- and second-line therapies constitute an important group that
might still retain good performance status and be amenable to
further life-prolonging therapy. In this setting, single-agent regor-
afenib represents a reasonable treatment option.14
Future Perspectives
Choosing Among Therapies: The Need for Biomarkers
One of the major unresolved issues in second-line therapy relates
to identifying the subset of patients who would be more appropriate
to receive bevacizumab versus ziv-aﬂibercept, because both agents are
now indicated as treatment options for patients in whom an initial
bevacizumab-containing regimen has failed. Ziv-aﬂibercept might
be indicated in patients whose disease progresses quickly, within the
ﬁrst 3 months of bevacizumab therapy, because this particular
patient population was not directly evaluated in the ML18147 trial.
However, this issue can only be conclusively resolved using a direct
head-to-head comparison of bevacizumab versus ziv-aﬂibercept in
the second-line setting, with appropriate stratiﬁcation of patients.
As noted, there are potentially important biological differences
between these 2 antiangiogenic agents, although the precise clinical
signiﬁcance of these differences remains unknown. Ziv-aﬂibercept
would appear to expand the potential range of angiogenic targets
beyond VEGF-A to include VEGF-B and PlGF, and there might be
an as yet undeﬁned subset of patients who would directly beneﬁt
from this agent versus narrowly targeted bevacizumab that targets
only VEGF-A. Cytotoxic chemotherapy has been found to up-
regulate PlGF in tumor cells, and antibodies to PlGF have dem-
onstrated antitumor effects in various preclinical models.20,59
Additional pathways involving PlGF might also contribute to
resistance to antiangiogenic therapy.21,60 PlGF has also been shown
to be upregulated in mCRC patients after bevacizumab-only ther-
apy, after treatment with the combination of FOLFIRI with bev-
acizumab, and before the development of progressive disease.50
These ﬁndings, although still largely correlative, highlight the
potential beneﬁt of expanding the range of antiangiogenic targets in
the VEGF signaling pathway, which could be of beneﬁt in the face
of dynamic and continually evolving tumor resistance mechanisms.
In addition, the enhanced binding of ziv-aﬂibercept to VEGF-A,
as observed in preclinical ﬁndings, could potentially be relevant in
the event that enhanced VEGF-A production alone is the driving
factor in bevacizumab resistance. In a recent review, LambrechtsClinical Colorectal Cancer September 2014et al61 examined the use of biomarkers to predict bevacizumab
treatment outcome. Overall, such biomarkers have proven difﬁcult
to identify and validate. This ﬁnding might be, in part, because of
the complexity of angiogenesis, an adaptive process that involves
a whole host of factors in addition to VEGF-A; thus, its inhibition
by bevacizumab can be potentially compensated by many other
angiogenic factors and cytokines/chemokines. However, emerging
evidence indicates that measurement of the short forms of VEGF-A,
which are generated through alternative splicing and can diffuse
over long distances, might provide a more speciﬁc assessment of the
actual tumor-produced VEGF-A.61 In addition, there is emerging
evidence that low VEGFR-1 expression at baseline, and low expres-
sion of neuropilin-1 (a VEGF coreceptor) at baseline, improves
outcome with bevacizumab.61,62 Because of these ﬁndings, it will be
of interest to determine whether use of a more broadly targeted
antiangiogenic agent, such as ziv-aﬂibercept, is beneﬁcial to patients
who are anticipated to have a poor response to bevacizumab in
the second-line setting (ie, those with high baseline VEGFR-1 or
neuropilin-1).61
There has been signiﬁcant focus placed on identifying potential
biomarkers predictive of regorafenib efﬁcacy. Markers suggestive
of regorafenib-mediated inhibition of angiogenesis, tyrosine kinase
receptors, and p38 MAP kinase pathway are some of the areas
of ongoing research. Biomarker analysis from the phase I study of
single-agent regorafenib in refractory mCRC patients revealed that
VEGFR-2 levels decreased while VEGF levels increased during the
periods of exposure to regorafenib.63 From that same study, tumor
blood ﬂow, determined using dynamic contrast-enhanced magnetic
resonance imaging decreased with regorafenib exposure. The pat-
terns of changes in these various biomarkers were consistent with
the antiangiogenic activity of regorafenib, although not predictive of
clinical beneﬁt.63
Other Agents in Development: Targeted Receptor
Inhibitors
Bevacizumab is a speciﬁc inhibitor of VEGF-A only, and it is
known that VEGF-A can bind either VEGFR-1 or VEGFR-2
(Fig. 1).8-10 It is not known whether a different therapeutic
approach—ie, direct targeting of the receptor, as opposed to the
ligand—might be of beneﬁt in patients who develop resistance to
antiangiogenic therapy while using bevacizumab. There are presently
2 different monoclonal antibodies that are under development, and
the clinical results might provide a better understanding of this
important issue.2 Ramucirumab (IMC-1121B) is a fully human
IgG1 that binds to VEGFR-2, thereby inhibiting its activation by
VEGF-A and its biologic activity, assessed according to tumor per-
fusion and vascularity.64 The initial phase I study reported 1 CRC
patient, previously treated with anti-VEGF therapy, who showed
stable disease for 15 weeks with ramucirumab therapy at a dose of
10 mg/kg.65 Garcia-Carbonero et al reported on the results of a
phase II study of ramucirumab in combination with folinic acid,
5-FU, and oxaliplatin (FOLFOX6) in the ﬁrst-line treatment of
mCRC (n ¼ 48). This combination regimen had an overall RR of
67% and median PFS of 11.5 months (95% CI, 9-13). Five of 48
patients had complete response. Overall, this regimen was well tol-
erated, and the most common severe adverse events were hyper-
tension (15%) and diarrhea (2%).66 A phase III, placebo-controlled
James J. Lee, Edward Chustudy of ramucirumab (IMC-1121B) combined with FOLFIRI in
the second-line setting is currently under way.67 A second antibody,
IMC-18F1 (ircrucumab), is directed against VEGFR-1, and it blocks
binding to and activation by the ligands VEGF-A, VEGF-B, and
PlGF.68 Lorusso et al reported on a phase I study of IMC-18F1,
showing tumor stabilization in 3 among 8 mCRC patients, but no
actual tumor response.69 The most common toxicities were fatigue,
nausea/vomiting, peripheral edema, anemia, and dyspnea.69 A phase
II study is currently under way comparing modiﬁed FOLFOX6
(mFOLFOX6) in combination with IMC-18F1 or ramucirumab,
or mFOLFOX6 alone in patients with mCRC whose disease has
progressed after a ﬁrst-line irinotecan-based regimen.2,70
Conclusion
The current standard of care for the ﬁrst-line treatment of mCRC
is combination cytotoxic chemotherapy using the ﬂuoropyrim-
idine backbone (5-FU or capecitabine) with either oxaliplatin
(FOLFOX or XELOX) or irinotecan (FOLFIRI) in combination
with bevacizumab or anti-EGFR agents, (eg, cetuximab or panitu-
mumab), for patients with wild type KRAS.2-7 The choice between
bevacizumab and anti-EGFR agents for the ﬁrst-line setting in
patients with wild type KRAS depends on clinical presentation and
individual patient factors. The ML18147 and VELOUR studies
have provided important clinical evidence for the beneﬁt of con-
tinued use of antiangiogenic therapies after progression during
previous bevacizumab therapy in the ﬁrst-line setting. With the
availability of ziv-aﬂibercept and regorafenib, treatment options for
mCRC have increased. However, the optimal sequencing of these
antiangiogenic therapies after progression of disease during bev-
acizumab treatment remains unknown at this time, and it will likely
vary depending on patient tolerability, and tumor- and patient-
speciﬁc factors. It will also be essential to develop a series of bio-
markers that could be used to identify the subset of patients who
would beneﬁt from continued bevacizumab treatment as opposed
to switching to ziv-aﬂibercept in the second-line setting. Finally, as
results emerge from clinical trials of newer antiangiogenic agents
currently in development, it will be important to determine their
most appropriate and rational place in the treatment continuum.Acknowledgments
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